https://euhcvdb.ibcp.fr/euHCVdb/jsp/nomen_tab1.jsp) representing all HCV genotypes ("Consensus DRACH") had lower polymorphism scores than DRACH sites found in the JFH1 reference strain but not the consensus ("JHF1 DRACH"). The A residue was particularly low scoring (p=3.00x10
-11 ) in a t-test between Consensus DRACH and JHF1 DRACH, suggestive of conserved methylation. Scores for the R, C, and H residues were also significantly lower (p=3.95x10
-5 , 2.84x10 -5 , and 0.02, respectively). The set of four DRACH motif sites proximal to the E1 m 6 A peak we identified from MeRIP-seq data ("E1 m 6 A peak sites") showed generally lower scores than the JFH1 DRACH, although only the R and H positions were statistically significant (p=0.02 and p=0.04). A control set of all other DRACH motifs found in the E1 region of the reference strain ("Other E1 DRACH") showed no significant differences in SNP rates with the JFH1 DRACH. We calculated polymorphism scores after a multiple sequence alignment using MUSCLE, where the score per position = -100*sum(p*log(p)), and p = frequency of each A, C, G, or T as described by ViPR (http://www.viprbrc.org). "Consensus" indicates that each position in the alignment contains a base consistent with the motif in > 50% of sequences. 
SUPPLEMENTAL EXPERIMENTAL PROCEDURES
Plasmids. These plasmids have been described previously: pJFH1-QL/GLuc2A (Yamane et al., 2014) , psJFH1-p7+NS5B, which contains cell culture adaptive mutations in p7 (C766Y) and NS5B (R2676K) (Aligeti et al., 2015) , and pLEX-FLAG-YTHDF1, 2, 3 (Kennedy et al., 2016) . The following plasmids were constructed in this study: pEF-Tak-Flag-YTHDF1, 2, 3; psJFH1-p7+NS5B-E1 mut , pJFH1-QL/GLuc2A-E1 mut , psJFH1-p7+NS5B-GNN; psiCHECK2-HCV WT or HCV E1 mut ; and pSgCD81_1 and pSgCD81_2. All DNA sequences were verified by sequencing. FLAG-tagged YTHDF constructs were generated by cloning PCR amplified products (YTHDF1, MGC cloneID-BC050284; YTHDF2, MGC cloneID-BC002559; YTHDF3, MGC cloneID-BC052970) into the pEF-Tak expression vector using NotI and PmeI (Saito et al., 2007) . psJFH1-p7+NS5B-E1 mut (with nucleotide mutations A1285T, C1303T, C1315T, and C1378T) was generated by inserting a synthesized gBlock with the desired mutations (nt972-1749, Integrated DNA Technologies) into a pCR-TOPO holding vector containing the JFH1 sequence (nt97-4333), and mutant AgeI-KpnI digested fragment was then subcloned into psJFH1-p7+NS5B. A similar strategy using AgeI and KpnI was used to clone the pJFH1-QL/GLuc2A-E1 mut reporter plasmid. psJFH1-p7+NS5B-GNN was generated by site-directed mutagenesis to insert the lethal NS5B D318N and D319N mutations in a pCR-TOPO holding vector containing the psJFH1-p7+NS5B region between nt8155 and the spectinomycin resistance gene, and the HindIII-XbaI fragment subcloned into psJFH1-p7+NS5B. psiCHECK2-HCV WT or HCV E1 mut was generated by amplifying nt1233-1439 of JFH1 by PCR then subcloning into the XhoI-NotI sites of the psiCHECK22 vector (Promega). All nucleotide and amino acid positions refer to the JFH1 genome (GenBank accession number: AB047639).
For CRISPR-mediated gene knockout, we generated two expression plasmids encoding U6 promoter driven human CD81-specific guide RNAs (gRNAs) (Mali et al., 2013) . Two rounds of overlapping PCR were performed by amplifying a gRNA encoding plasmid (provided by George Church, Harvard University; Addgene plasmid # 41819): in the first round, PCR products were generated encompassing the U6 promoter through the 5′ end of the gRNA (consisting of the specific target sequence) with the ME-O-1122 oligonucleotide (5′-CGGGCCCCCCCTCGAGTGTACAAAAAAGCAGGCT) and a CD81 target sequence specific reverse oligonucleotide (see list below). A second PCR product was generated encompassing a region from the CD81 target sequence through the end of the gRNA coding sequence with a forward direction CLDN1 target sequence specific oligonucleotide (ME-O-1138; 5'-GCTTCATTCTCGCCTTCCGTTTTAGAGCTAGAAATA). These products were then reamplified with only the outer oligonucleotides, ME-O-1122 and -1123, to produce single PCR products flanked by XhoI and EcoRI sites at the 5′ and 3′ ends, respectively, and cloned into pBlueScript. Two separate CD81-specific gRNA plasmids were created with the following forward and reverse oligonucleotide combination: ME-O-1252/1251; 5'-GGGCTGCTACGGGGCCATC CGGTGTTTCGTCCTTTCC / 5'-GATGGCCCCGTAGCAGCCC GTTTTAGAGCTAGAAATA, and ME-O-1254/1253; 5'-TCTCGTGGAAGGTCTTCAC CGGTGTTTCGTCCTTTCC / 5'-CACCTGTACACGTAGGGCC GTGAAGACCTTCCACGAGA GTTTTAGAGCTAGAAATA, which target nucleotides 467-485 and 672-690 of the CD81 human cDNA (Genbank accession number: NM_004356), respectively. The sequences of oligonucleotide primers and plasmids used are available upon request.
In vitro transcription of HCV RNA and electroporation. Plasmid DNA encoding the described HCV constructs was linearized using XbaI. Linearized DNA treated with proteinase K (Thermo-Fisher) and Mung bean nuclease (NEB) was purified by phenol-chloroform extraction and was used as a template for in vitro transcription with a MEGAscript T7 Transcription Kit (Thermo-Fisher). Following DNase treatment, RNA was purified by phenolchloroform extraction and run on a denaturing gel to ensure integrity. For electroporation, 5µg of in vitro transcribed viral RNA was electroporated into 4x10 6 Huh7.5 cells at 250V and 950µF with a Gene Pulser Xcell system (BioRad).
Luciferase assays for HCV Replication. Huh7.5 CD81 KO cells cultured in 12-well plates were transfected with specific siRNAs. At 24 hours after siRNA treatment, 1µg of in vitro transcribed JFH1-QL/GLuc2A reporter HCV RNA was transfected into cells using the TransIT-mRNA transfection kit (Mirus Bio), according to the manufacturer's instructions. Gaussia luciferase activity in supernatant harvested at 4, 24, 48 and 72 hours posttransfection was measured using the BioLux Gaussia Luciferase assay kit (NEB).
Quantification of RNA by RT-qPCR. RNA was reversed transcribed using the iScript cDNA synthesis kit (BioRad) as per manufacturer's instructions, and synthesized cDNA was diluted 1:5 in water. RT-PCR was performed in triplicate with the Power SYBR Green PCR master mix (Thermo-Fisher) using the Applied Biosystems Step One Plus RT-PCR system. The sequences of primers used for RT-qPCR are:
Primer Name Primer Sequence
To measure extracellular HCV RNA, viral RNA from filtered cell supernatants was extracted using a QIAamp viral RNA kit (Qiagen), as recommended by the manufacturer. HCV RNA copy number was measured in triplicate by RT-qPCR using the TaqMan Fast Virus 1-Step Mix (Qiagen) with an HCV-specific probe targeting the 5' untranslated region of HCV (Assay ID: Pa03453408_s1). The copy number of HCV was calculated by comparison to a standard curve of a full-length in vitro transcribed HCV RNA, as described (Aligeti et al., 2015) .
Immunofluorescence analysis and confocal microscopy. Cells were fixed in 4% paraformaldehyde in PBS, permeabilized with 0.2% Triton X-100 in PBS, and blocked with 3% BSA in PBS. Slides were stained with antibodies against YTHDF1 (Proteintech, 1:100), YTHDF2 (Proteintech, 1:100), YTHDF3 (Sigma, 1:100), or FLAG (Sigma; 1:1000), and HCV core protein (Thermo-Fisher; 1:500), washed 3x with PBS, and stained with conjugated AlexaFluor secondary antibodies (Life Technologies), BODIPY 493/503 (Invitrogen; 1:150) along with DAPI (1:200, Life Technologies), and mounted with ProLong Gold (Invitrogen). Imaging was performed on a Zeiss 710 laser scanning confocal microscope, or a Leica SP5 inverted confocal microscope using a 63x/1.25 oil objective using 405, 488, 561 and 633 laser lines at a 4x optical zoom with pinholes set to 1 AU for each channel (Light Microscopy Core Facility, Duke University). Gain and offset settings were optimized and final images were taken with line averaging of 4. All images were processed with NIH Fiji/ImageJ (Schindelin et al., 2012) .
The enrichment index of YTHDF proteins measures the enrichment of YTHDF staining in the area proximal to lipid droplets, relative to that in the area distal to lipid droplets. This was calculated by using NIH Fiji/ImageJ to measure the mean brightness of YTHDF proteins in an area of 0.4µM around lipid droplets, as identified by BODIPY staining. Then, the YTHDF mean brightness in an area around the lipid droplets expanded by a further 0.4µM (between 0.4µM and 0.8µM) was subtracted from the first value.
Immunoblotting. Cells were lysed in a modified RIPA buffer (10mM Tris [pH 7.5], 150mM NaCl, 0.5% sodium deoxycholate, and 1% Triton X-100) supplemented with protease inhibitor cocktail (Sigma) and phosphatase inhibitor cocktail II (Millipore), and post-nuclear lysates were harvested by centrifugation. Quantified protein (between 5-15µg) was resolved by SDS/PAGE, transferred to nitrocellulose membranes in a 25 mM Tris-192 mM glycine-0.01% SDS buffer and blocked in StartingBlock (Thermo-Fisher) buffer. After washing with PBS-T buffer, membranes were incubated with species-specific horseradish peroxidase-conjugated antibodies (Jackson ImmunoResearch, 1:5000) followed by treatment of the membrane with ECL+ (GE Healthcare) and imaging on Xray film. The following antibodies were used for immunoblot: anti-METTL3 (Novus Biologicals, 1:5000), anti-METTL14 (Sigma, 1:5000), anti-FTO (Abcam, 1:1000), anti-YTHDF1 (Abcam, 1:1000), anti-YTHDF2 (Santa Cruz Biotechnology, 1:500), anti-YTHDF3 (Sigma, 1:1000), anti-ALKBH5 (Sigma, 1:1000), anti-FLAG M2 (Sigma, 1:5000), anti-tubulin (Sigma, 1:5000), anti-HCV NS5A (gift of Charles Rice, 1:1000), and anti-HCV Core (ThermoFisher, 1:500).
RNA-immunoprecipitation.
Cell extracts were harvested in polysome lysis buffer (100mM KCl, 5mM MgCl 2 , 10mM HEPES (pH 7.0), 0.5% Nonidet P-40 (NP-40)) supplemented with protease inhibitor cocktail (Sigma) and RNaseIN ribonuclease inhibitor (Promega), and lysates were cleared by centrifugation. RNP complexes were immunoprecipitated with anti-FLAG antibody conjugated to magnetic beads (Sigma) overnight at 4°C with headover-tail rotation, and then washed five times in ice-cold NT2 buffer (50mM Tris-HCl (pH 7.4), 150mM NaCl, 1mM MgCl 2 , 0.05% NP-40). Protein for immunoblotting was eluted from ten percent of beads by boiling in 2X Laemmli sample buffer (Bio-Rad). RNA was extracted from ninety percent of beads using TRIzol reagent (Thermo-
